NLRP3 and diabetic kidney disease: This is in line with previous studies, performed in murine models of diabetic nephropathy, bladder inflammation, and acute kidney injury, showing that the pharmacological blockade of P2X4 receptors blunted the IL-1β release through the inhibition of NLRP3 inflammasome pathway [31, 37, 38].